Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -5256.80% is 399% below its 5-year average of -1053.00%, near the high end of its 5-year range (-54742.00%–557.74%).
2513.76% below its 12-month average of -201.12%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
-5256.80%
NET PROFIT MARGIN AVG TTM
-201.12%
NET PROFIT MARGIN AVG 3Y
-921.08%
NET PROFIT MARGIN AVG 5Y
-1053.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2513.76%
CURRENT VS 3Y AVG
-470.72%
CURRENT VS 5Y AVG
-399.22%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-2021746.15%
vs the sector median at left
Shattuck Labs, Inc.
Market Cap
$539.41M
Net Profit Margin
-5256.80%
TTM Avg
-201.12%
3Y Avg
-921.08%
5Y Avg
-1053.00%
Market Cap
$534.64M
Net Profit Margin
-10599.76%
TTM Avg
-44116.54%
3Y Avg
-22058.27%
5Y Avg
-14705.51%
Market Cap
$535.09M
Net Profit Margin
0.56%
TTM Avg
-33.88%
3Y Avg
-929.83%
5Y Avg
-984.73%
Market Cap
$538.76M
Net Profit Margin
-41.34%
TTM Avg
-365.72%
3Y Avg
-7572.59%
5Y Avg
-5048.40%
Market Cap
$533.38M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$547.30M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$520.84M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$523.79M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$520.25M
Net Profit Margin
-921.50%
TTM Avg
-767.53%
3Y Avg
-527.58%
5Y Avg
-706.89%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | $539.41M | -5256.80% | -201.12% | -921.08% | -1053.00% |
| ProKidney Corp. (PROK)vs › | $534.64M | -10599.76% | -44116.54% | -22058.27% | -14705.51% |
| Delcath Systems, Inc. (DCTH)vs › | $535.09M | 0.56% | -33.88% | -929.83% | -984.73% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $538.76M | -41.34% | -365.72% | -7572.59% | -5048.40% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $533.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Monopar Therapeutics Inc. (MNPR)vs › | $547.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $520.84M | 0.00% | 0.00% | 0.00% | 0.00% |
| Immix Biopharma, Inc. (IMMX)vs › | $523.79M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $520.25M | -921.50% | -767.53% | -527.58% | -706.89% |
| Altimmune, Inc. (ALT)vs › | $520.22M | -296000.00% | -345077.99% | -146585.06% | -98190.17% |
Operating Margin
-5150.8%
Net Profit Margin
-5256.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | -1005.60% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | -556.39% |
| 2024-06-30 | -1339.47% |
| 2024-03-31 | -1659.55% |
| 2023-12-31 | -2477.17% |
| 2023-09-30 | -4014.72% |
| 2023-06-30 | -10673.00% |
| 2023-03-31 | -36357.89% |
| 2022-12-31 | -6515.64% |
| 2022-09-30 | -11620.28% |
| 2022-06-30 | -54742.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 26.09% |
| 2021-09-30 | -916.32% |
| 2021-06-30 | 557.74% |
| 2021-03-31 | -520.40% |
| 2020-12-31 | -895.08% |
| 2020-09-30 | -485.79% |
| 2020-06-30 | -195.16% |
| 2020-03-31 | -220.23% |
| 2019-12-31 | -261.22% |
| 2019-09-30 | -408.02% |
| 2019-06-30 | -176.71% |
| 2019-03-31 | -176.71% |
